Abstract
Bacteria use multiple strategies to bypass the inflammatory responses in order to survive in the host cells. In this review, we discuss the mechanism of the bacerial proteins in inhibiting inflammation. We highlight the antiinflammatory roles of the type three secretion proteins including Salmonella AvrA, Enteropathogenic Escherichia coli Cif, and Yersinia YopJ, Staphylococcus aureus extracellular adherence protein, and Chlamydia proteins. We also discuss the research progress on the structures of these anti-inflammatory bacterial proteins. The current therapeutic methods for diseases, such as inflammatory bowel diseases, sclerosis, lack influence on the course of chronic inflammation and infection. Therefore, based on the molecular mechanism of the anti-inflammatory bacterial proteins and their 3-Dimension structure, we can design new peptides or non-peptidic molecules that serve as anti-inflammatory drugs without the possible side effect of promoting bacterial infection.
Keywords: Bacteria, type three secretion system, effector, bacterial-tail-specific protease, inflammation, anti-inflammation, acetylation, ubiquitination, phosphorylation, intestine
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host
Volume: 8 Issue: 3
Author(s): Jun Sun
Affiliation:
Keywords: Bacteria, type three secretion system, effector, bacterial-tail-specific protease, inflammation, anti-inflammation, acetylation, ubiquitination, phosphorylation, intestine
Abstract: Bacteria use multiple strategies to bypass the inflammatory responses in order to survive in the host cells. In this review, we discuss the mechanism of the bacerial proteins in inhibiting inflammation. We highlight the antiinflammatory roles of the type three secretion proteins including Salmonella AvrA, Enteropathogenic Escherichia coli Cif, and Yersinia YopJ, Staphylococcus aureus extracellular adherence protein, and Chlamydia proteins. We also discuss the research progress on the structures of these anti-inflammatory bacterial proteins. The current therapeutic methods for diseases, such as inflammatory bowel diseases, sclerosis, lack influence on the course of chronic inflammation and infection. Therefore, based on the molecular mechanism of the anti-inflammatory bacterial proteins and their 3-Dimension structure, we can design new peptides or non-peptidic molecules that serve as anti-inflammatory drugs without the possible side effect of promoting bacterial infection.
Export Options
About this article
Cite this article as:
Sun Jun, Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (3) . https://dx.doi.org/10.2174/187152309789151986
DOI https://dx.doi.org/10.2174/187152309789151986 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease
Current Rheumatology Reviews Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design Design and Synthesis of Novel Anti-inflammatory/Anti-ulcer Hybrid Molecules with Antioxidant Activity
Medicinal Chemistry Prokaryotic Substrate-Binding Proteins as Targets for Antimicrobial Therapies
Current Drug Targets Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Infectious Disorders - Drug Targets Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design Proteomics Analysis: A Powerful Tool to Identify Proteome Phenotype and Proteome Signature in Enterococcus faecalis
Current Proteomics Gut Microbiota of Obese, Type 2 Diabetic Individuals is Enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after Weight Loss
Endocrine, Metabolic & Immune Disorders - Drug Targets Cefixime-induced Oromandibular Dystonia in an Adult: A Case Report
Current Drug Safety Mass Spectrometry-Based Approaches for the Detection of Proteins of Staphylococcus Species
Infectious Disorders - Drug Targets Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Daptomycin: A Review of Properties, Clinical Use, Drug Delivery and Resistance
Mini-Reviews in Medicinal Chemistry Mechanisms of β -lactam Resistance Among Pseudomonas aeruginosa
Current Pharmaceutical Design Acute Tonsillitis
Infectious Disorders - Drug Targets Emerging Electrical Biosensors for Detecting Pathogens and Antimicrobial Susceptibility Tests
Current Organic Chemistry